⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nanofin SCHEMBL25816 | 1.00 | — | — | |
| Nanofin SCHEMBL13248931 | 1.00 | — | — | |
| Nanofin SCHEMBL1548552 | 1.00 | — | — | |
| Nanofin SCHEMBL1548548 | 1.00 | — | — | |
| Nanofin SCHEMBL83612 | 1.00 | — | — | |
| Nanofin SCHEMBL24269496 | 1.00 | — | — | |
| Nanofin SCHEMBL11617103 | 0.96 | — | — | |
| Nanofin SCHEMBL2857389 | 0.96 | — | — | |
| Nanofin SCHEMBL21219257 | 0.96 | — | — | |
| Nanofin SCHEMBL18003135 | 0.96 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110105346-B | Optionally substituted quinoline compounds | 卫材R&D管理有限公司 | 2023-03-10 | — | — | CN | disclosed |
| EP-3995495-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | Eisai R&D Management Co., Ltd. (JP) | 2022-05-11 | — | — | EP | disclosed |
| EP-3626717-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | Eisai R&D Management Co., Ltd. (JP) | 2020-03-25 | — | — | EP | disclosed |
| US-20180354939-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2018-12-13 | — | — | US | disclosed |
| US-10087174-B2 | Selectively substituted quinoline compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2018-10-02 | — | — | US | disclosed |
| US-20180030045-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2018-02-01 | — | — | US | disclosed |
| US-20160326161-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-11-10 | — | — | US | disclosed |
| EP-3057420-A1 | USE OF PESTICIDAL ACTIVE CARBOXAMIDE DERIVATIVE IN SOIL AND SEED APPLICATION AND TREATMENT METHODS | BASF Agrochemical Products B.V. (NL) | 2016-08-24 | — | — | EP | disclosed |
| EP-3057964-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | Eisai R&D Management Co., Ltd. (JP) | 2016-08-24 | — | — | EP | disclosed |
| WO-2016038067-A1 | USE OF AFIDOPYROPENE IN GENETICALLY MODIFIED PLANTS | BASF SE (DE) | 2016-03-17 | — | — | WO | disclosed |
| WO-2014096374-A1 | PROCESS FOR THE SYNTHESIS OF PYRROLIDINES AND PYRROLES | SANDOZ AG (CH) | 2014-06-26 | — | — | WO | disclosed |
| WO-2014057079-A1 | PREPARATION OF ERTAPENEM INTERMEDIATES | SANDOZ AG (CH) | 2014-04-17 | — | — | WO | disclosed |
| EP-1945621-A1 | PROCESS TO PREPARE AMINO ACID DERIVATIVES | Dow Gloval Technologies Inc. (US) | 2008-07-23 | — | — | EP | disclosed |
| EP-1773835-A2 | PYRIDO-PYRIDO-PYRIMIDINE DERIVATIVES, PREPARATION THEREOF, THERAPEUTIC USE THEREOF FOR TREATING CANCER | Sanofi-Aventis (FR) | 2007-04-18 | — | — | EP | disclosed |
| WO-2007038116-A1 | PROCESS TO PREPARE AMINO ACID DERIVATIVES | DOW GLOBAL TECHNOLOGIES INC. (US) | 2007-04-05 | — | — | WO | disclosed |
| EP-1725239-A1 | 4-(SULFANYL-PYRIMIDIN-4-YLMETHYL)-MORPHOLINE DERIVATIVES AND RELATED COMPOUNDS AS GABA RECEPTOR LIGANDS FOR THE TREATMENT OF ANXIETY, DEPRESSION AND EPILEPSY | F.HOFFMANN-LA ROCHE AG (CH) | 2006-11-29 | — | — | EP | disclosed |
| EP-1687288-A1 | SUBSTITUTED ARYL CYCLOALKANOL DERIVATIVES AND METHODS OF THEIR USE | Wyeth (US) | 2006-08-09 | — | — | EP | disclosed |
| WO-2006016067-A2 | PYRIDO-PYRIDO PYRIMIDINE DERIVATIVES, PREPARATION THEREOF, THERAPEUTIC USE THEREOF FOR TREATING CANCER | SANOFI-AVENTIS (FR) | 2006-02-16 | — | — | WO | disclosed |
| WO-2005094828-A1 | 4- (SULFANYL-PYRIMIDIN-4-YLMETHYL) -MORPHOLINE DERIVATIVES AND RELATED COMPOUNDS AS GABA RECEPTOR LIGANDS FOR THE TREATMENT OF ANXIETY, DEPRESSION AND EPILEPSY | F. HOFFMANN-LA ROCHE AG (CH) | 2005-10-13 | — | — | WO | disclosed |
| WO-2005037809-A1 | SUBSTITUTED ARYL CYCLOALKANOL DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2005-04-28 | — | — | WO | disclosed |